Apogee Therapeutics (APGE) to Release Quarterly Earnings on Monday

Key Points

• Apogee Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($1.08) per share.
• The company recently reported a higher loss of ($0.95) EPS in its previous quarter, exceeding analysts' expectations of ($1.19) per share.
• Apogee Therapeutics has received multiple analyst upgrades, maintaining a consensus rating of "Buy" with an average price target of $99.00.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Stock Performance

Shares of Apogee Therapeutics stock traded down $0.61 during trading on Friday, hitting $35.39. The company's stock had a trading volume of 622,255 shares, compared to its average volume of 676,257. The company has a fifty day simple moving average of $40.18 and a two-hundred day simple moving average of $38.03. The company has a market capitalization of $1.63 billion, a PE ratio of -9.83 and a beta of 1.43. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $63.50.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 2,725 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $37.78, for a total transaction of $102,950.50. Following the completion of the sale, the insider directly owned 236,273 shares in the company, valued at approximately $8,926,393.94. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 15,540 shares of company stock worth $658,625. 42.77% of the stock is currently owned by company insiders.

Institutional Trading of Apogee Therapeutics

Large investors have recently made changes to their positions in the stock. Creative Planning bought a new stake in shares of Apogee Therapeutics in the second quarter worth approximately $392,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after acquiring an additional 694 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Apogee Therapeutics by 100.0% in the first quarter. Millennium Management LLC now owns 260,335 shares of the company's stock worth $9,726,000 after acquiring an additional 130,164 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on APGE shares. Guggenheim reiterated a "buy" rating and issued a $116.00 price target on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. Citigroup restated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, July 7th. BTIG Research raised their price objective on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Finally, Wedbush restated an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday, July 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $99.00.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.